BioSpace News Archive

IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation cryoablation technology that destroys tumors by freezing, announced today that it has been granted Designation as a Breakthrough Device from the U.S. Food and Drug Administration (FDA) for its lead asset, ProSense®, and proposed indication for use

Twist Bioscience (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, is proud to be Certified™ by Great Place to Work®.

n-Lorem Foundation, a nonprofit organization that provides free, lifetime supplies of individualized RNA-targeted medicines to patients living with ultra-rare diseases, today announced a new partnership with Ultragenyx Pharmaceutical (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases.

Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE: AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced that Amneal Pharmaceuticals LLC (“Amneal”), a subsidiary of the Company, has completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“Kashiv Specialty”),

Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the appointment of Richard Eisenstadt as Chief Financial Officer. Mr. Eisenstadt is an accomplished pharmaceutical industry executive with more than 20 years of experience in leading finance and accounting operations

Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that multiple presentations on the impact of metabolic acidosis and CKD and data on veverimer will be given at the National Kidney Foundation 2021 Spring Clinical Meeting

WebSafety, Inc. (www.websafety.com) (OTCMarkets: VDXI). WebSafety announced today that the company has successfully completed the acquisition of VeriDetx Inc.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion during the virtual Longwood Healthcare Leaders 2021 Webconference taking place April 5-6.

BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a leading pre-clinical-stage biotechnology company focused on harnessing elements of perinatal tissue for use in regenerative therapies, today reported financial results for the three and twelve months ended December 31, 2020.

SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, announced today that the PARIS® Test was utilized in a study to identify novel drug targets and combinations to combat ovarian clear cell carcinoma (OCCC)